Literature DB >> 3477566

Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography.

P A Maessen1, K B Mross, H M Pinedo, W J van der Vijgh.   

Abstract

4'-Epidoxorubicin, its seven metabolites and doxorubicin, as internal standard, were efficiently extracted from plasma using C18 Sep-Pak cartridges. The recoveries ranged from 58% for doxorubicin aglycone up to 98% for 4'-epidoxorubicin glucuronide. The anthracyclines were separated by reversed-phase high-performance liquid chromatography within 9 min and analysed by fluorescence. The assay was sensitive to 3 X 10(-10) M for the glucuronides up to 12 X 10(-10) M for 7-deoxydoxorubicin aglycone. The peak-height ratio of the fluorescence intensities of the anthracyclines versus doxorubicin showed a linear correlation with the concentration from the detection limit up to 2.5 X 10(-7) M (correlation coefficient r2 greater than 0.99). Within-day and between-day precision of the assay were in the ranges 2-14% (n = 6) and 2-11% (n = 6), respectively.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3477566     DOI: 10.1016/0378-4347(87)80127-5

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Sensitive absorption-based wave-mixing detector for anthracycline drugs separated by capillary electrophoresis.

Authors:  Sandrine Berniolles; Hongjing Kan; William G Tong
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2010-06-23       Impact factor: 4.098

2.  Metabolism of epidoxorubicin in animals: absence of glucuronidation.

Authors:  P A Maessen; K B Mross; H M Pinedo; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Authors:  K Mross; K Hamm; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.

Authors:  O Y Hu; S P Chang; J M Jame; K Y Chen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.

Authors:  W J van der Vijgh; P A Maessen; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

7.  Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.

Authors:  L K Webster; E J Cosson; K H Stokes; M J Millward
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.